New Tariff Plans May Raise Costs for Aesthetic Pharmaceuticals

The President announced plans to impose a 100% tariff on branded and patented pharmaceutical products imported into the U.S. starting October 1.

While the announcement has raised concerns about higher consumer costs and slowed drug development, there are key exemptions:

• Generic drugs (which make up 90% of U.S. prescriptions) are not affected.
• Pharmaceutical companies with U.S.-based manufacturing or those actively building facilities may be exempt, but only for the specific products made domestically.
• Countries with trade agreements, like those in the European Union, are expected to remain under a 15% tariff cap, not the full 100%.

This means products like Restylane (made in Sweden) and Ozempic (primarily made in Denmark) may fall under the lower tariff, while others like Botox (exclusively produced in Ireland) or Jeuveau (made in South Korea) could be subject to this 100% tariff, depending on manufacturing details and trade status.

While the full impact remains unclear, cost increases for imported aesthetic pharmaceuticals may be passed down to practices and patients. Industry professionals should monitor supplier communications and prepare for potential pricing shifts.

Read more at NBC News >>